- Home
- Equipment
- canada alberta
- gene therapy vectors
Refine by
Gene Therapy Vectors Equipment & Supplies In Canada Alberta
5 equipment items found
Premium
Manufactured by:AB Sciex LLC based inFramingham, MASSACHUSETTS (USA)
Perform consistent and compliant biotherapeutics characterization faster than ever. With the PA 800 Plus system, you can confidently safeguard the success of your biologics. Run multiple characterizations from a single system that biopharma labs depend on, and produce qualitative and quantitative analyses, with speed and ...
by:Expression Systems, LLC based inDavis, CALIFORNIA (USA)
ESF AF™ Insect Cell Culture Medium is an Animal Origin-Free formulation and is a complete serum-free, protein-free medium developed for robust cell growth, protein expression and baculovirus vector production for a wide range of insect cells including Sf9, Sf21, Tni, and Drosophila S2. ESF AF medium is comparable to ESF 921 for growth and expression. ESF AF contains L-Glutamine and ...
Manufactured by:Newcells Biotech Limited based inNewcastle Upon Tyne, UNITED KINGDOM
A functional monolayer in vitro model of retinal pigment epithelial cells generated from human iPSCs for accurate prediction of clinical outcomes. The retinal pigment epithelial (RPE) cell model is composed of a monolayer of RPE cells cultured in 24-well Transwell® plates. RPE characterisation includes: morphology assessment, pigmentation, RPE-specific expression at the protein level (BEST1, ...
Manufactured by:ProBioGen AG based inBerlin, GERMANY
ProBioGen recognized the need to overcome the limits of existing virus and viral vector production. Therefore, we created well defined, permanent cell lines for scalable and flexible virus production systems. All our proprietary cell lines are characterized by excellent productivity, safety, and stability. They are used in the industrial production of virus-based vaccines or recombinant proteins ...
by:Neurona Therapeutics based inSouth San Francisco, CALIFORNIA (USA)
Neurona’s lead product candidate, NRTX-1001, comprises human MGE-type inhibitory GABAergic interneurons derived from pluripotent stem cells. NRTX-1001’s first indication is for the treatment of drug-resistant focal epilepsy, which is a major unmet need affecting approximately one-third of people living with epilepsy. Epileptic seizures are characterized by imbalanced neural activity ...